Introduction

This article is based on work produced by the Lipedema Foundation, presented in their Four Lipedema Controversies document prepared for the Boston Lymphatic Symposium (BLS). The document synthesises current research and highlights areas of uncertainty, limitation and clinical relevance in lipoedema. What follows is a clinical interpretation of that work for Lipedema Lounge. All primary sources remain the intellectual work of their original authors, as collated and summarised by the Lipedema Foundation.

Lipoedema sits at a difficult intersection of lived experience, clinical observation and a developing research base. As a result, it is an area where certainty is often overstated and nuance is lost. The Lipedema Foundation’s document does not attempt to provide definitive answers. Instead, it sets out four areas of ongoing controversy and examines what the evidence currently supports, what it does not, and where caution is required.

Is Lipoedema a Lymphatic Disease, and Is There True Oedema?

One of the most persistent questions in lipoedema management is whether it should be considered a lymphatic disorder and whether oedema is a defining feature. The Lipedema Foundation’s synthesis shows that lymphatic dysfunction is frequently associated with lipoedema.

Since 2012, most studies examining lymphatic structure or function report abnormalities, and many individuals describe symptomatic improvement with lymphatic-targeted therapies such as compression and manual lymphatic drainage. Co-existing lymphoedema is reported in approximately 20% of people diagnosed with lipoedema.
However, the Lipedema Foundation is careful to distinguish association from causation.

Many studies do not adequately control for obesity or overall adiposity, making it difficult to determine whether lymphatic changes are primary, secondary or a later consequence of disease progression. Evidence for true oedema is inconsistent, with wide variation in definitions, assessment tools and imaging methods. Findings from MRI and ICG lymphography suggest that lipoedema can exist without measurable lymphatic impairment, while other presentations appear to sit along a spectrum that includes subclinical oedema or evolving lymphatic involvement. The implication is not that lymphatic involvement is irrelevant, but that lipoedema should not be reduced to a purely lymphatic diagnosis.

What Role Does Obesity Play in Symptoms and Progression?

Obesity is commonly observed alongside lipoedema, but the Lipedema Foundation stresses that it is not the same condition. Reported prevalence of obesity in lipoedema varies widely, reflecting differences in study design, diagnostic criteria and populations studied. Crucially, there is little evidence that obesity itself drives lipoedema progression.

Research examining progression is limited overall. Available data suggest that increases in limb volume may be more closely related to central weight gain than to lipoedema-specific adipose tissue alone. Weight loss typically reduces truncal fat but has limited impact on affected limbs, a pattern frequently reported by patients. Bariatric surgery may reduce limb volume in some cases, but pain and bruising often persist or worsen.

Emerging data on incretin-based therapies (gut hormones, GLP1 agonists) suggest potential improvements in symptoms, including pain, but the Foundation highlights the need for robust clinical trials before conclusions can be drawn. High reported rates of disordered eating in people with lipoedema reinforce the importance of avoiding weight-centred or stigmatising narratives in clinical care.

How Common is Lipoedema, and is it Overdiagnosed?

Estimates of lipoedema prevalence range from less than 1% to over 10%, largely due to inconsistent diagnostic criteria and low-quality epidemiological data. Large, population-based studies using standardised diagnostic frameworks are currently lacking.
The Lipedema Foundation notes that underdiagnosis is likely to be a greater problem than overdiagnosis. Historically, lipoedema has been misattributed to obesity, venous disease or lymphoedema, often resulting in long diagnostic delays. Central adiposity does not exclude lipoedema, yet this misconception continues to influence clinical decision-making.

While overdiagnosis may occur in specific contexts, such as self-diagnosis or the use of vague criteria, this does not negate the broader issue of under-recognition. The Foundation supports symptom-driven, cautious diagnostic approaches, with conservative management considered appropriate even when diagnostic certainty is incomplete.

How Common is Pain, and What Causes It?

Pain is a common but complex feature of lipoedema. The Lipedema Foundation frames pain as a biopsychosocial phenomenon shaped by biological, psychological and social factors. Simplistic descriptions of lipoedema as “painful fat” are considered inaccurate and potentially harmful.

Many individuals report pain, discomfort or sensory changes such as heaviness, tightness and hypersensitivity. Pain prevalence and severity appear to increase with disease stage, severity and age. Some evidence suggests a somatic component to pain, including altered pressure or vibration sensitivity, but these findings are based on small studies with methodological limitations.

The Foundation also cautions against dismissing psychological pain. Doing so contributes to stigma and delays appropriate care. Pain assessment in lipoedema requires nuance, individualisation and clinical humility.

What the Lipedema Foundation’s Work Makes Clear

Across all four controversies, several consistent themes emerge. Lipoedema is likely underdiagnosed, and comorbidity is common. Conservative therapies benefit many people, even when underlying mechanisms remain unclear. The current research base is limited, and certainty should be avoided.

The Lipedema Foundation explicitly warns against the uncritical use of terms such as “myth” and “fact” in a field where evidence is still emerging. Rather than offering definitive answers, the document provides a framework for more careful, evidence-informed discussion. It calls for better study design, clearer definitions and more responsible communication, while acknowledging the lived realities of those affected.

References

Fife, C.E., Maus, E.A. and Carter, M.J. (2020) ‘Lipedema: A frequently misunderstood fat disorder’, Journal of the American Board of Family Medicine, 33(3), pp. 454–463.

Alencar, A., Pereira Nascimento, A. and Anooshiravani, N. (2022) ‘Lipedema: A contemporary review of the influence of obesity, treatment recommendations, and opportunities for research’, Frontiers in Endocrinology, 13, 910910.

Naouri, M., Samimi, M., Soret, J., Perrodeau, E., Branche, G. and Le Pillouer-Prost, A. (2023) ‘High prevalence of lipedema in patients consulting for peripheral edema: An observational study of 194 cases’, Aesthetic Surgery Journal, 43(2), pp. 232–242.